Table 1.
Baseline characteristics and qualifying genomics by group.
| Characteristic | Group 1 (n = 16) | Group 2 (n = 32) | ||
|---|---|---|---|---|
| No. | % | No. | % | |
| Median age, years (range) | 56 (23–71) | 54 (20–76) | ||
| Male sex | 8 | 50% | 13 | 41% |
| ECOG status | ||||
| 0 | 15 | 94% | 24 | 75% |
| 1 | 1 | 6% | 8 | 25% |
| Lines of prior systemic treatment | ||||
| Median line (range) | 1.5 (1–3) | 2 (0–5) | ||
| Prior lines <2 | 8 | 50% | 9 | 28% |
| Cancer type | ||||
| Bone and soft tissue sarcomas | 4 | 25% | 8 | 25% |
| Alveolar soft part sarcoma | 1 | 3% | ||
| Chondrosarcoma | 2 | 6% | ||
| Ewing’s sarcoma | 1 | 3% | ||
| Leiomyosarcoma | 2 | 13% | 2 | 6% |
| Liposarcoma | 2 | 6% | ||
| Osteosarcoma | 1 | 6% | 1 | 3% |
| PEComa | 1 | 6% | ||
| Carcinomas | 12 | 75% | 24 | 75% |
| Anal, SCC | 1 | 3% | ||
| Breast, IDC | 2 | 6% | ||
| Cervix adenocarcinoma | 1 | 6% | ||
| Cholangiocarcinoma, gallbladder adenocarcinoma | 2 | 13% | ||
| Colorectal adenocarcinoma | 1 | 6% | 3 | 9% |
| CUP | 1 | 3% | ||
| Endometrial adenocarcinoma | 2 | 6% | ||
| Ethmoid sinus adenocarcinoma | 1 | 6% | ||
| Gastric adenocarcinoma | 1 | 6% | 1 | 3% |
| Glioma | 1 | 6% | 2 | 6% |
| Medulloblastoma | 1 | 3% | ||
| Meningioma, anaplastic | 1 | 3% | ||
| Neuroendocrine carcinoma | 1 | 3% | ||
| Ovarian adenocarcinoma | 1 | 3% | ||
| Ovarian, sex cord-stromal tumour | 1 | 3% | ||
| Pancreas adenocarcinoma | 4 | 25% | 2 | 6% |
| Small intestine adenocarcinoma | 1 | 6% | 1 | 3% |
| Thyroid carcinoma, papillary | 1 | 3% | ||
| Uveal melanoma | 2 | 6% | ||
| Qualifying genomic biomarker | ||||
| BRCA1 | 4^ | 25% | ||
| BRCA2 | 12 | 75% | ||
| ATM | 10# | 31% | ||
| ATR | 1 | 3% | ||
| BAP1 | 2 | 6% | ||
| BARD1 | 1* | 3% | ||
| BRIP1 | 2$ | 6% | ||
| CDK12 | 3+* | 3% | ||
| CHEK1 | 1 | 3% | ||
| CHEK2 | 3 | 9% | ||
| FANCA | 2* | 6% | ||
| FANCI | 1 | 3% | ||
| NBN | 1 | 3% | ||
| RAD51 | 1 | 3% | ||
| SLX4 | 2* | 6% | ||
| XRCC2 | 1 | 3% | ||
CUP carcinoma of unknown primary, HRR homologous recombination repair, IDC infiltrating ductal carcinoma, PEComa perivascular epithelioid cell tumour, SCC squamous cell carcinoma.
*Indicates alterations that would not pass current bioinformatic pipelines, but were included in the original molecular tumour board report that qualified patients for the trial, comprised of 1 BARD1, 1 CDK12, 1 FANCA, 1 ATM + CHEK1, 1 CHEK1 and both SLX4 alterations. ^Two patients with a qualifying BRCA1 alteration also had a co-occurring HRR gene alteration (1 in ATM and the other in FANCD2); #four patients with qualifying ATM alterations also had co-occurring HRR gene alterations (2 in CHEK1, 1 in NBN, 1 in CHEK1 and BARD1 and 1 in CHEK1 and RAD51); $one patient with a qualifying BRIP1 alteration also had a RAD51C mutation; +two patients with qualifying CDK12 alterations also had a RAD51 mutation, or a RAD51 and FANCE mutation.